- Home
- DYAI vs NRXP Comparison
DYAI vs NRXP Comparison
Compare DYAI & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- NRXP
- Stock Information
- Founded
- DYAI 1979
- NRXP 2015
- Country
- DYAI United States
- NRXP United States
- Employees
- DYAI N/A
- NRXP N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- DYAI Health Care
- NRXP Health Care
- Exchange
- DYAI Nasdaq
- NRXP Nasdaq
- Market Cap
- DYAI 28.3M
- NRXP 32.6M
- IPO Year
- DYAI 2004
- NRXP N/A
- Fundamental
- Price
- DYAI $1.01
- NRXP $2.98
- Analyst Decision
- DYAI Strong Buy
- NRXP Strong Buy
- Analyst Count
- DYAI 1
- NRXP 4
- Target Price
- DYAI $6.00
- NRXP $28.50
- AVG Volume (30 Days)
- DYAI 58.3K
- NRXP 187.5K
- Earning Date
- DYAI 08-12-2025
- NRXP 08-13-2025
- Dividend Yield
- DYAI N/A
- NRXP N/A
- EPS Growth
- DYAI N/A
- NRXP N/A
- EPS
- DYAI N/A
- NRXP N/A
- Revenue
- DYAI $3,554,344.00
- NRXP N/A
- Revenue This Year
- DYAI $22.56
- NRXP N/A
- Revenue Next Year
- DYAI $30.95
- NRXP N/A
- P/E Ratio
- DYAI N/A
- NRXP N/A
- Revenue Growth
- DYAI 57.59
- NRXP N/A
- 52 Week Low
- DYAI $0.91
- NRXP $1.10
- 52 Week High
- DYAI $2.20
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- DYAI 55.41
- NRXP 42.62
- Support Level
- DYAI $0.91
- NRXP $2.89
- Resistance Level
- DYAI $1.03
- NRXP $3.53
- Average True Range (ATR)
- DYAI 0.05
- NRXP 0.16
- MACD
- DYAI 0.01
- NRXP -0.07
- Stochastic Oscillator
- DYAI 83.00
- NRXP 15.52
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.